BioSpace News Archive

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has priced its previously announced offering of $1,250,000,000 aggregate principal amount of 5.000% senior notes due 2028 (the “2028 Notes”) and $1,250,000,000 aggregate principal amount of 5.250% senior notes due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”).

Responds to Misleading Statements Made by CEO Daniel J. O’Connor to Secure Approval for the China Grand Takeover.

FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo

HitGen Inc. announced that HitGen and Mitsubishi Tanabe Pharma Corporation have entered into a license agreement to develop a novel class of drugs.

Taro Pharmaceutical Industries Ltd. announced the preliminary results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal value NIS 0.0001 per share, which expired at 5:00 p.m., New York City time, on Monday, December 16, 2019.

Neoleukin Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share.

With the latest approval, Xtandi, an androgen receptor inhibitor, is now the only oral treatment approved by the FDA for three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.

GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.

The trial met its primary efficacy endpoint and all tested secondary endpoints.

Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.